Replication-Defective Arenavirus Vectors for Safe Antigen Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Arenaviruses have not been effectively utilized as vaccine vectors due to their potential to cause overwhelming infection and immunosuppression, and the challenge of incorporating foreign antigens for optimal immune response.
Innovation Solution
Engineering arenaviruses to be replication-deficient in normal cells while allowing gene expression, by removing or mutating key open reading frames and introducing foreign nucleic acids under control of viral and cellular promoters, with internal ribosome entry sites for enhanced expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If arenaviruses are used as vaccine vectors, then strong and long-lasting immune responses are elicited, but overwhelming infection and immunosuppression occur
Solution Approach 1:
The patent removes or mutates key viral genes (NP, L, Z) from the arenavirus genome to create replication-deficient vectors. This extraction of essential viral components eliminates the virus's ability to replicate and cause disease while preserving the immunogenic glycoprotein envelope that elicits strong immune responses. The removed genes are the specific elements causing harmful effects, while the retained envelope maintains beneficial immunogenicity.
Solution Approach 2:
The patent segments the arenavirus genome into essential replication genes (NP, L, Z) and immunogenic envelope genes (GP). By separating these functions and eliminating the replication genes, the vector retains immune-stimulating capabilities without pathogenic potential. This segmentation allows independent optimization of safety and immunogenicity.
2Adaptability or versatility
If foreign antigens are incorporated into arenavirus vectors, then immune response to target antigen is enhanced, but the virus can still cause disease
Solution Approach 1:
The patent extracts and removes the viral replication genes (NP, L, Z) from the arenavirus genome, creating a replication-deficient backbone that cannot cause disease. This allows safe incorporation of foreign antigens into the viral envelope without the risk of viral replication and pathogenesis. The extraction enables versatile antigen loading while eliminating harmful replication capacity.
3Productivity
If replication-competent arenaviruses are used, then viral amplification occurs, but immunosuppression and severe disease result
Solution Approach 1:
The patent removes the RNA-dependent RNA polymerase gene (L) and other essential replication genes (NP, Z) from the arenavirus genome. This extraction eliminates the virus's ability to amplify and replicate within host cells, preventing immunosuppression and severe disease. The resulting replication-deficient vector cannot produce progeny virus particles, ensuring safety while maintaining immunogenicity.
Data Source
AI summary
The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.